Regeneron Pharmaceuticals' Research & Development rose 1515.47% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.9 billion, marking a year-over-year increase of 1399.45%. This contributed to the annual value of $5.9 billion for FY2025, which is 1399.45% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Research & Development stood at $1.6 billion, which was up 1515.47% from $1.5 billion recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Research & Development registered a high of $1.6 billion during Q4 2025, and its lowest value of $665.4 million during Q3 2021.
In the last 5 years, Regeneron Pharmaceuticals' Research & Development had a median value of $1.1 billion in 2023 and averaged $1.1 billion.
In the last 5 years, Regeneron Pharmaceuticals' Research & Development tumbled by 280.46% in 2021 and then surged by 4141.81% in 2022.
Regeneron Pharmaceuticals' Research & Development (Quarter) stood at $737.6 million in 2021, then skyrocketed by 41.42% to $1.0 billion in 2022, then rose by 12.86% to $1.2 billion in 2023, then grew by 19.95% to $1.4 billion in 2024, then grew by 15.15% to $1.6 billion in 2025.
Its Research & Development stands at $1.6 billion for Q4 2025, versus $1.5 billion for Q3 2025 and $1.4 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value